CO2018007442A2 - Vacunas contra el cáncer - Google Patents

Vacunas contra el cáncer

Info

Publication number
CO2018007442A2
CO2018007442A2 CONC2018/0007442A CO2018007442A CO2018007442A2 CO 2018007442 A2 CO2018007442 A2 CO 2018007442A2 CO 2018007442 A CO2018007442 A CO 2018007442A CO 2018007442 A2 CO2018007442 A2 CO 2018007442A2
Authority
CO
Colombia
Prior art keywords
immunogenic
polypeptide
polypeptides
nucleic acid
taa
Prior art date
Application number
CONC2018/0007442A
Other languages
English (en)
Inventor
Joseph John Binder
Helen Kim Cho
Paul Jason Cockle
Derek John Falconer
Siradanahalli Guru
Karin Ute Jooss
Marianne Marcela Andrea Martinic
Kenneth Nelson Wills
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CO2018007442A2 publication Critical patent/CO2018007442A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente divulgación proporciona (a) polipéptidos aislados de TAA inmunogénico (es decir, un polipéptido de MUC1 inmunogénico, un polipéptido de MSLN inmunogénico, y un polipéptido de TERT inmunogénico), (b) moléculas aisladas de ácido nucleico que codifican uno o más polipéptidos de TAA inmunogénico, (c) composiciones de vacuna que comprenden un polipéptido de TAA inmunogénico o una molécula aislada de ácido nucleico que codifica un polipéptido de TAA inmunogénico, y (d) métodos relacionados con los usos de los polipéptidos, moléculas de ácido nucleico y composiciones.
CONC2018/0007442A 2016-01-19 2018-07-16 Vacunas contra el cáncer CO2018007442A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662280636P 2016-01-19 2016-01-19
US201662419190P 2016-11-08 2016-11-08
PCT/IB2017/050229 WO2017125844A1 (en) 2016-01-19 2017-01-16 Cancer vaccines

Publications (1)

Publication Number Publication Date
CO2018007442A2 true CO2018007442A2 (es) 2018-07-31

Family

ID=57960563

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0007442A CO2018007442A2 (es) 2016-01-19 2018-07-16 Vacunas contra el cáncer

Country Status (22)

Country Link
US (3) US10251944B2 (es)
EP (2) EP3733201A1 (es)
JP (2) JP6820935B2 (es)
KR (2) KR102158923B1 (es)
CN (1) CN108778321A (es)
AU (1) AU2017208848A1 (es)
BR (1) BR112018013967A2 (es)
CA (1) CA2954892A1 (es)
CO (1) CO2018007442A2 (es)
DK (1) DK3405212T3 (es)
ES (1) ES2811523T3 (es)
HU (1) HUE051722T2 (es)
IL (2) IL260321B (es)
MX (1) MX2018008797A (es)
PH (1) PH12018501532A1 (es)
PL (1) PL3405212T3 (es)
PT (1) PT3405212T (es)
RU (2) RU2020110148A (es)
SG (1) SG11201805621SA (es)
SI (1) SI3405212T1 (es)
TW (3) TWI654302B (es)
WO (1) WO2017125844A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204760A1 (en) * 2017-05-05 2018-11-08 David Weiner Ctla4 antibodies and vaccine combinations and use of same for immunotherapy
CN117940152A (zh) * 2021-06-09 2024-04-26 阿尔特有限公司 缀合物

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
CA1341482C (en) 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
JPH0662517B2 (ja) 1985-01-07 1994-08-17 シンテツクス（ユー・エス・エイ）インコーポレイテツド 置換アルキルートリ置換アンモニウム界面活性剤
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5591624A (en) 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE69034168T3 (de) 1989-03-21 2013-04-11 Vical, Inc. Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5817491A (en) 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
EP0615453B1 (en) 1991-11-29 1997-05-14 Chiron Viagene, Inc. Anti-cancer immunotherapeutic vector constructs
PL170980B1 (pl) 1992-06-25 1997-02-28 Smithkline Beecham Biolog Szczepionka PL PL PL PL PL PL PL
IL107366A (en) 1992-10-23 2003-03-12 Chugai Pharmaceutical Co Ltd Genes coding for megakaryocyte potentiator
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5651981A (en) 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
US5527928A (en) 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
ATE254931T1 (de) 1996-01-05 2003-12-15 Us Gov Health & Human Serv Mesothelinantigen, verfahren und testsatz zur targetierung
US7375183B1 (en) 1996-01-05 2008-05-20 The United States Of America As Represented By The Department Of Health And Human Services Mesothelin, immunogenic peptides derived therefrom, and compositions comprising mesothelin, or immunogenic peptides thereof
WO1997034921A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Conjugated mucin peptide vaccines
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
ES2205132T5 (es) 1996-10-01 2012-06-18 Geron Corporation Subunidad catalítica de la telomerasa humana
US6475789B1 (en) 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6093809A (en) 1996-10-01 2000-07-25 University Technology Corporation Telomerase
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
PT1005368E (pt) 1997-03-10 2009-11-19 Coley Pharm Gmbh Utilização de ácidos nucleicos contendo dinucleótidos cpg não metilados em combinação com alúmen como adjuvante
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US20050013825A1 (en) 1997-04-18 2005-01-20 Geron Corporation Vaccine containing the catalytic subunit of telomerase for treating cancer
WO1998052581A1 (en) 1997-05-20 1998-11-26 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
JP4280309B2 (ja) 1997-06-06 2009-06-17 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア Ｄｎａ免疫刺激配列活性の阻害剤
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
US6337200B1 (en) 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
US6962790B1 (en) 1998-09-23 2005-11-08 University Of Massachusetts Medical Center Predictive assay for immune response
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
EP1880735A3 (en) 1999-03-19 2008-03-12 GlaxoSmithKline Biologicals S.A. Vaccine
EP2322210A1 (en) 1999-04-19 2011-05-18 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
US6472028B1 (en) 1999-08-12 2002-10-29 Joseph Frazzitta Method of producing a high gloss coating on a printed surface
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
CO5200837A1 (es) 1999-09-24 2002-09-27 Smithkline Beecham Corp Vacunas
WO2001021152A1 (en) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
GB9930359D0 (en) 1999-12-22 2000-02-09 Glaxo Group Ltd Novel polypeptides
AU2001241533A1 (en) 2000-02-15 2001-08-27 The Regents Of The University Of California A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
AU2001282290A1 (en) 2000-08-17 2002-03-04 University Of Wales College Of Medicine Htert-immortalised cell lines, their preparation and use
US20040136963A1 (en) 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
US20030143228A1 (en) 2001-10-29 2003-07-31 Baylor College Of Medicine Human telomerase reverse transcriptase as a class-II restricted tumor-associated antigen
TWI228718B (en) 2001-11-05 2005-03-01 Tdk Corp Manufacturing method and device of mold plate for information medium
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
GB0212046D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
JP2006521090A (ja) 2002-07-12 2006-09-21 ザ ジョンズ ホプキンス ユニバーシティー メゾテリンワクチンおよびモデルシステム
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
CN1315536C (zh) * 2002-09-13 2007-05-16 李进 肿瘤抗原疫苗及其制备方法和疫苗组合物
DK1711518T3 (da) 2004-01-23 2010-04-06 Angeletti P Ist Richerche Bio Vaccinebærere for chimpanse-adenovirus
DE102004035227A1 (de) 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
US7829294B2 (en) * 2004-12-28 2010-11-09 Daiichi Pure Chemicals Co., Ltd. Anti-human soluble fibrin monoclonal antibody and immunological assay method using the antibody
EP1748067A1 (en) 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
WO2007094924A2 (en) 2006-01-19 2007-08-23 The Regents Of The University Of California Human telomerase reverse transcriptase peptides
WO2008043760A1 (en) * 2006-10-12 2008-04-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof
EP1994942A1 (en) 2007-05-25 2008-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions comprising telomerase, and uses thereof
WO2009025871A1 (en) 2007-08-23 2009-02-26 University Of Medicine And Dentistry Of Nj Telomerase reverse transcriptase variant
RS53688B9 (sr) 2008-07-08 2020-01-31 Incyte Holdings Corp 1,2,5-oksadiazoli kao inhibitori indoleamin 2,3-dioksigenaze
AU2010209938A1 (en) 2009-02-02 2011-08-25 Glaxosmithkline Biologicals Sa Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
CN101920009B (zh) 2010-03-06 2012-08-08 河北医科大学 一种用于预防和治疗肿瘤的疫苗
EP2714081A4 (en) * 2011-05-27 2015-09-09 Cytocure Llc METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT
JP2014521657A (ja) 2011-07-27 2014-08-28 ベイラー リサーチ インスティテュート 膵臓がんに対する樹状細胞（ｄｃ）ワクチン療法
US8523590B2 (en) * 2011-07-29 2013-09-03 General Electric Company Cable system and methods of assembling a cable system
RU2017143985A (ru) * 2011-08-17 2019-02-14 Глоубиммьюн, Инк. Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения
SG10201603896RA (en) * 2012-05-04 2016-07-28 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
US10184216B2 (en) * 2012-07-18 2019-01-22 Thomas Urbanek Advantageous detectable warning area and methods of forming the same
US10137182B2 (en) * 2013-02-14 2018-11-27 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
EA201992251A1 (ru) 2013-03-15 2020-05-08 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Противораковые вакцины и способы лечения с их применением
BR112016008806A2 (pt) 2013-11-01 2017-10-03 Pfizer Vetores para expressão de antígenos associados à próstata
KR101873672B1 (ko) 2014-05-15 2018-07-02 아이테오스 테라퓨틱스 Ｉｄｏ１ 억제제로서 사용하기 위한 피롤리딘-２,５-디온 유도체, 제약 조성물 및 방법

Also Published As

Publication number Publication date
US10251944B2 (en) 2019-04-09
US11058753B2 (en) 2021-07-13
KR102158923B1 (ko) 2020-09-23
RU2018126487A3 (es) 2020-02-20
US20190142918A1 (en) 2019-05-16
JP6820935B2 (ja) 2021-01-27
PL3405212T3 (pl) 2020-11-16
RU2018126487A (ru) 2020-02-20
SG11201805621SA (en) 2018-08-30
PH12018501532A1 (en) 2019-05-15
JP2021061851A (ja) 2021-04-22
PT3405212T (pt) 2020-08-25
EP3733201A1 (en) 2020-11-04
TWI654302B (zh) 2019-03-21
BR112018013967A2 (pt) 2019-02-05
HUE051722T2 (hu) 2021-03-29
TW201738377A (zh) 2017-11-01
IL277752A (en) 2020-11-30
CN108778321A (zh) 2018-11-09
TWI709647B (zh) 2020-11-11
IL260321B (en) 2020-10-29
CA2954892A1 (en) 2017-07-19
IL260321A (en) 2018-08-30
RU2718663C2 (ru) 2020-04-13
KR20180101537A (ko) 2018-09-12
WO2017125844A1 (en) 2017-07-27
US20170202938A1 (en) 2017-07-20
RU2020110148A (ru) 2020-09-18
US20220323558A1 (en) 2022-10-13
TW202111125A (zh) 2021-03-16
TW201932598A (zh) 2019-08-16
DK3405212T3 (da) 2020-08-24
MX2018008797A (es) 2018-11-29
EP3405212A1 (en) 2018-11-28
AU2017208848A1 (en) 2018-07-12
EP3405212B1 (en) 2020-07-08
JP2019505210A (ja) 2019-02-28
KR20200109395A (ko) 2020-09-22
ES2811523T3 (es) 2021-03-12
SI3405212T1 (sl) 2020-09-30

Similar Documents

Publication Publication Date Title
CY1123932T1 (el) Δομες πολυειδικου αντισωματος
BR112018011073A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização
CY1125084T1 (el) Εμβολια νουκλεϊκου οξεος
PE20142406A1 (es) Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
CY1122372T1 (el) Συνθεση ρινικου εμβολιου γριπης
CY1125392T1 (el) Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων
BR112018073628A2 (pt) anticorpos antimiostatina e métodos de utilização
BR112018013930A2 (pt) vírus oncolítico, vírus que expressa três genes heterólogos, composição farmacêutica, vírus para o uso, produto de fabricação, método de tratamento de câncer e uso do vírus
CO2018009120A2 (es) Genes del factor viii optimizados
CR20170282A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
CR20170326A (es) Anticuerpos antimiostatina, polipéptidos que contienen regiones fc variantes, y métodos de uso
AR088693A1 (es) Anticuerpos especificos para trop-2 y sus usos
AR105470A1 (es) Métodos para inducir una respuesta inmune
BR112015025748A2 (pt) construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna
BR112018073221A2 (pt) métodos de previsão da utilidade de proteínas ou seus fragmentos, métodos de seleção e/ou avaliação de modificações de aminoácidos específicas, método de fornecimento de vacinas e vacina
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
AR102950A1 (es) Variantes de lipasa y polinucleótidos que las codifican
BR112019005516A2 (pt) novo sítio de inserção do ehv orf70
CL2018000164A1 (es) Vector recombinante del virus orf.
CO2021013417A2 (es) Arn del replicón-lnp oncolítico sintético y usos para la inmunoterapia contra el cáncer
BR112018014042A2 (pt) vírus do tipo orthomyxo da tilápia.
CL2019000705A1 (es) Nuevos promotores.
CO2018007442A2 (es) Vacunas contra el cáncer